- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06577025
Um estudo de diferentes sequências de Cilta-cel, Talquetamabe em combinação com Daratumumabe e Teclistamabe em combinação com Daratumumabe após indução com Daratumumabe, Bortezomibe, Lenalidomida e Dexametasona em participantes com mieloma múltiplo recém-diagnosticado de risco padrão (aMMbition)
Um estudo aberto de fase 2 para avaliar a eficácia e segurança de diferentes sequências de Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC em combinação com Daratumumab SC (Tal-D) e Teclistamab SC em combinação com Daratumumab SC (Tec-D ) Após indução com daratumumabe, bortezomibe, lenalidomida e dexametasona (DVRd) em participantes com mieloma múltiplo recém-diagnosticado de risco padrão
The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negativity with complete response/stringent complete response (CR/sCR) and a positron emission tomography/computed tomography (PET/CT) scan that does not show any signs of cancer at 5 years. MRD negativity and CR/sCR is defined as no detectable signs of remaining cancer cells after the treatment. This study will also characterize how well the treatments administered work in the study through progression-free survival (PFS). PFS is defined as the length of time during and after the treatment of a disease, that a participant lives with the disease, but it does not get worse.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Heidelberg, Alemanha, 69120
- Universitaetsklinikum Heidelberg
-
Tübingen, Alemanha, 72076
- Universitaetsklinikum Tuebingen
-
Würzburg, Alemanha, 97080
- Universitatsklinikum Wurzburg
-
-
-
-
-
Melbourne, Austrália, 3004
- The Alfred Hospital
-
Melbourne, Austrália, 3000
- Peter MacCallum Cancer Centre
-
-
-
-
-
Salvador, Brasil, 41253-190
- IDOR - Regional Bahia
-
São Paulo, Brasil, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasil, 05652 900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
-
-
-
-
Madrid, Espanha, 28041
- Hosp. Univ. 12 de Octubre
-
Salamanca, Espanha, 37007
- Hosp Clinico Univ de Salamanca
-
Santander, Espanha, 39008
- Hosp. Univ. Marques de Valdecilla
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- City of Hope
-
San Francisco, California, Estados Unidos, 94143
- University of California San Francisco
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa Hospital and Clinics
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Levine Cancer Institute
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Participants with documented new diagnosis of multiple myeloma (MM) according to international myeloma working group (IMWG) diagnostic criteria and with no prior myeloma-directed therapy
- Participants must have standard-risk MM (stage I and II) based on revised International Staging System (R-ISS)
- Participants must be considered fit (score equals to [=] 0) or intermediate-fit (score=1) according to IMWG Frailty Index assessment (based on the Charlson Comorbidity Index, the Katz Activity of Daily Living and the Lawson Instrumental Activities of Daily Living)
- Measurable disease defined as: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) (>=10 gram per liter [g/L] for institutions using alternative units) or urine M-protein level >= 200 milligrams per 24 hours (mg/24 hours); Light chain MM without measurable disease in the serum or the urine: Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (>=100 mg/L for institutions using alternative units) and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
Exclusion Criteria:
- Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM). Any history of malignancy, other than MM, which is considered at high risk of recurrence requiring systemic therapy
- Peripheral neuropathy or neuropathic pain of Grade >= 2, as defined by National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
- Known active or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM
- Stroke or seizure within 6 months of signing the informed consent form (ICF)
- Plasma cell leukemia at the time of diagnosis or any time thereafter through apheresis (>= 5 percent [%] circulating plasma cells in peripheral blood smears), Waldenstrom macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes(POEMS) syndrome, or primary amyloid light chain amyloidosis with associated organ dysfunction
- Presence of high-risk disease features: (a) Cytogenetic high risk lesions by MM fluorescence in situ hybridization (FISH) including deletion 17p (del[17p])/, t(4;14), t(14;16), amplification 1q (amp[1q21]) (>= 4 copies); (b) Presence of 1 or more extramedullary plasmacytomas
- Seropositive for human immunodeficiency virus (HIV)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cohort A: DVRd Induction + Tal-D Consolidation + Cilta-cel
Participants will undergo apheresis followed by 4 cycles of DVRd induction (each cycle is of 28 days) and cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release, and completion of induction, participants will begin consolidation with 4 cycles of Tal-D (each cycle is of 28 days), followed by a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days); cilta-cel will be administered 5 to 7 days after the start of the conditioning regimen. |
Talquetamab will be administered subcutaneously.
Outros nomes:
Cilta-cel infusion will be administered intravenously.
Outros nomes:
Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
Outros nomes:
Bortezomib will be administered subcutaneously as a part of induction. Lenalidomide will be administered orally as a part of induction. Dexamethasone will be administered orally as a part of induction. Cyclophosphamide will be administered intravenously as a part of conditioning regimen. Fludarabine will be administered intravenously as a part of conditioning regimen. |
|
Experimental: Cohort B: DVRd Induction + Cilta-cel + Tal-D and Tec-D Consolidation
Participants will undergo apheresis followed by 4 cycles of DVRd induction and Cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release and completion of induction, participants will begin consolidation with a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days) with infusion of cilta-cel 5 to 7 days after the start of the conditioning regimen. Following cilta-cel infusion, alternating cycles of Tal-D (Cycle 1, 3, 5, and 7) and Tec-D (Cycle 2, 4, 6, and 8) will be started, no earlier than Day 84 and no later than Day 168 post cilta-cel infusion. Each cycle of Tal-D or Tec-D is 84 days which includes an extended treatment-free interval. |
Talquetamab will be administered subcutaneously.
Outros nomes:
Teclistamab will be administered subcutaneously.
Outros nomes:
Cilta-cel infusion will be administered intravenously.
Outros nomes:
Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
Outros nomes:
Bortezomib will be administered subcutaneously as a part of induction. Lenalidomide will be administered orally as a part of induction. Dexamethasone will be administered orally as a part of induction. Cyclophosphamide will be administered intravenously as a part of conditioning regimen. Fludarabine will be administered intravenously as a part of conditioning regimen. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Rate of Response with Curative Potential
Prazo: Up to 5 years
|
Rate of Response with curative potential is defined as the percentage of participants with a composite of durable (at least 2 years) minimal residual disease (MRD) (10^-5) negativity with complete response/stringent complete response (CR/sCR) by serology and negative positron emission tomography/computed tomography (PET/CT) imaging at 5-years after start of induction therapy. This includes: negative imaging at 5-year landmark time; MRD-negative status (at 10^-5) in 2 bone marrow examinations that are a minimum of 2 years apart; response of CR or better per the International Myeloma Working Group (IMWG) criteria; no examination showing MRD-positive status or relapse from CR in between assessments. |
Up to 5 years
|
|
Progression Free Survival (PFS) Rate at 3-Year
Prazo: At 3-year
|
PFS is defined as the time from the date of randomization to either progressive disease (PD), according to the IMWG response criteria, or death, whichever occurs first. |
At 3-year
|
|
PFS Rate at 5-Year
Prazo: At 5-year
|
PFS is defined as the time from the date of randomization to either PD, according to the IMWG response criteria, or death, whichever occurs first. |
At 5-year
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall response rate (ORR; Partial response [PR] or better)
Prazo: Up to 5 years
|
ORR (PR or better) is defined as the percentage of participants with best overall response of PR or better according to IMWG response criteria. |
Up to 5 years
|
|
CR or Better Rate
Prazo: Up to 5 years
|
Rate of CR or better is defined as the percentage of participants with best overall response of CR or better according to IMWG response criteria. |
Up to 5 years
|
|
Very Good Partial Response (VGPR) or Better Rate
Prazo: Up to 5 years
|
Rate of VGPR or better is defined as the percentage of participants with best overall response of VGPR or better rate according to IMWG response criteria. |
Up to 5 years
|
|
Duration of Response (DOR)
Prazo: Up to 5 years
|
DOR is calculated among responders (with a PR or better response) from the date of initial documented response (PR or better) to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first. |
Up to 5 years
|
|
Time to First Response (TTR)
Prazo: Up to 5 years
|
Time to response (that is, time to first response) is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better based on the computerized algorithm per IMWG criteria for those who had PR or better as their best response. |
Up to 5 years
|
|
Duration of CR or Better Response
Prazo: Up to 5 years
|
Duration of CR or better response is calculated among responders (with a CR or better response) from the date of initial documented response CR or better to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first. |
Up to 5 years
|
|
Time to First CR or Better Response
Prazo: Up to 5 years
|
Time to first CR or better response is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for CR or better based on the computerized algorithm per IMWG criteria. |
Up to 5 years
|
|
PFS on next line therapy (PFS2)
Prazo: Up to 5 years
|
PFS2 is defined as time from randomization to progression on the next line of therapy or death, whichever comes first. |
Up to 5 years
|
|
Overall Survival (OS)
Prazo: Up to 5 years
|
OS is measured from the date of randomization to the date of death due to any cause. |
Up to 5 years
|
|
MRD-negative CR Rate
Prazo: Up to 5 years
|
MRD-negative CR is defined as the percentage of participants who achieved both CR or better and MRD negativity at a threshold of 10^-5 and 10^-6. MRD-negative CR rate will be evaluated at the first occurrence from induction treatment initiation for participants per IMWG criteria. |
Up to 5 years
|
|
Number of Participants with Treatment-emergent Adverse Events (TEAEs) by Severity
Prazo: Up to 5 years
|
An Adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse events. |
Up to 5 years
|
|
Change from baseline in Health-related quality of life (HRQoL) (symptoms and functioning) using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core 30 item instrument (EORTC-QLQ-C30)
Prazo: Up to 5 years
|
Change from baseline in participants' HRQoL (symptoms and functioning) as assessed by EORTC-QLQ-C30 will be reported. The EORTC-QLQ-C30 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, social), 1 global health status scale, 3 symptom scales (pain, fatigue, nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). The recall period is 1 week ("past week") and responses are reported using a verbal rating scale. The item and scale scores are transformed to a 0-to-100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms. |
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Vasculares
- Doenças cardiovasculares
- Neoplasias
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Neoplasias de Células Plasmáticas
- Distúrbios hemostáticos
- Paraproteinemias
- Distúrbios das Proteínas Sanguíneas
- Distúrbios hemorrágicos
- Doenças hemic e linfáticas
- Mieloma múltiplo
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Hidrocarbonetos
- Ácidos carboxílicos
- Compostos policíclicos
- Piperidinas
- Produtos químicos inorgânicos
- Pregada
- Pregnas
- Esteróides
- Compostos de anel fundido
- Esteróides, fluorados
- Mustarazas de fosforamida
- Compostos de mostarda de nitrogênio
- Compostos de mostarda
- Hidrocarbonetos, halogenados
- Fosforamidas
- Compostos organofosforos
- Pregadienetriols
- Ácidos borônicos
- Ácidos, não carboxílico
- Ácidos
- Compostos de boro
- Pirazinas
- Ftalimidas
- Ácidos ftaléticos
- Ácidos, carbocíclicos
- Piperidones
- Isoindoles
- Lenalidomida
- Bortezomibe
- Dexametasona
- Ciclofosfamida
- fludarabina
- daratumumab
- Talquetamab
Outros números de identificação do estudo
- 54767414MMY2093
- 54767414MMY2093 (Outro identificador: Janssen Research & Development, LLC)
- 2023-505792-71-00 (Identificador de registro: EUCT number)
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .